<div id="readability-page-1"><p>Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The company traded as high as $28.25 and last traded at $28.5290, with a volume of 68587 shares changing hands. The stock had previously closed at $26.40.</p><div><p><span></span><span>Get <strong>Tyra Biosciences</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>TYRA has been the subject of several recent analyst reports. Wall Street Zen raised shares of Tyra Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Wedbush increased their price target on Tyra Biosciences from $30.00 to $37.00 and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, December 16th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Oppenheimer  reaffirmed an &#34;outperform&#34; rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. One investment analyst  has rated the stock with a Strong Buy rating, four have issued  a Buy rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $34.20.</p><p><b>Check Out Our Latest Stock Report on TYRA</b></p><h2>Tyra Biosciences Trading Up 9.9%</h2><p>The stock's fifty day moving average price is $20.93 and its 200 day moving average price is $15.06. The stock has a market cap of $1.55 billion, a P/E ratio of -15.42 and a beta of 1.07. </p><p>Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting analysts' consensus estimates of ($0.50).  On average, analysts anticipate that  Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares of the company's stock, valued at approximately $95,585,625. The trade was a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 15.20% of the stock is owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently bought and sold shares of the business. Federated Hermes Inc. lifted its holdings in shares of  Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company's stock valued at $30,000 after purchasing an additional 1,841 shares during the last quarter.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of  Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock worth $126,000 after acquiring an additional 1,668 shares during the last quarter.  SG Americas Securities LLC bought a new position in shares of  Tyra Biosciences during the third quarter valued at $133,000.  Public Employees Retirement System of Ohio purchased a new position in shares of  Tyra Biosciences in the 2nd quarter worth about $177,000.  Finally, Russell Investments Group Ltd. boosted its stake in  Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company's stock worth $178,000 after purchasing an additional 2,766 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors. </p><h2>Tyra Biosciences Company Profile</h2> (Get Free Report)<p>Tyra Biosciences <span>NASDAQ: TYRA<span></span></span> is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.  </p><p>The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Tyra Biosciences</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Do not delete, read immediately</li><li>You Still Think Silver’s a Joke? Watch What Happens Next.</li><li>This stock gets a 94 out of 100</li><li>Punch these codes into your ordinary brokerage account</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tyra Biosciences Right Now?</h2><p>Before you consider Tyra Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.</p><p>While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TYRA

<p>Tyra Biosciences (NASDAQ:TYRA) reached a new 52-week high of $28.53, up from a previous close of $26.40. Analysts have mixed ratings, with one Strong Buy, four Buy, and one Sell. The average target price is $34.20. The company reported an EPS of -$0.50, meeting expectations. Insider trading saw Director Robert J. More sell 10,000 shares. Institutional investors hold 84.14% of the stock. Tyra focuses on developing therapies for genetically defined cancers.</p>

Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month High - Here's Why